GSE247146

Blood gene expression biomarkers of response to anti-TNF drugs in pediatric patients before initiation of treatment

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

24 case / 0 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

Background/aims: Changes in gene expression profiles among individuals with inflammatory bowel diseases (IBDs) could potentially influence the responsiveness to anti-TNF treatment. The aim of this study was to identify genes that could serve as predictors of early response to anti-TNF therapies in pediatric IBD patients prior to the initiation of treatment.Methods: We conducted a prospective, longitudinal, and multicenter study, enrolling 24 pediatric IBD patients aged less than 18 years who were initiating treatment with either infliximab or adalimumab. RNA-seq from blood samples was analyzed using the DESeq2 library by comparing responders and non-responders to anti-TNF drugs. Results: Bioinformatic analyses unveiled 102 differentially expressed genes, with 99 genes exhibiting higher expression in responders compared to non-responders prior to the initiation of anti-TNF therapy. Functional enrichment analyses highlighted defense response to Gram-negative bacteria (FDR =2.3 ×10–7) as the most significant biological processes, and hemoglobin binding (FDR =0.002), as the most significant molecular function. Gene Set Enrichment Analysis (GSEA) revealed notable enrichment in transcriptional misregulation in cancer (FDR =0.016). Notably, 13 genes (CEACAM8, CEACAM6, CILP2, COL17A1, OLFM4, INHBA, LCN2, LTF, MMP8, DEFA4, PRTN3, AZU1, and ELANE) were selected for validation, and a consistent trend of increased expression in responders prior to drug administration was observed for most of these genes, with findings for 4 of them being statistically significant (CEACAM8, LCN2, LTF2, and PRTN3). Conclusions: We identified 102 differentially expressed genes involved in the response to anti-TNF drugs in children with IBDs and validated CEACAM8, LCN2, LTF2, and PRTN3. Genes participating in defense response to Gram-negative bacterium, serine-type endopeptidase activity, and transcriptional misregulation in cancer are good candidates for anticipating the response to anti-TNF drugs in children with IBDs.

Overall design

Expression profiling by high throughput sequencing. Whole gene expression profiles from total RNA isolated from whole-blood samples of children with inflammatory bowel disease of 12 responders and 12 non-responders taken before biologic administration were analyzed by RNA next-generation sequencing. The other 12 samples were taken from GSE159034.

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
24 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

1 linked publication 1 DOI

Primary publication

  1. Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024
Available

Metadata Quality Components

Analysis Readiness

Not ready
55% DE readiness

Contrast completeness

10/25 pts

Only one side of the contrast is present; downstream DE needs both groups.

Minimum group size

0/20 pts

Minimum group size cannot be evaluated until a complete contrast exists.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

0/10 pts

Critical warnings must be resolved before downstream analysis.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

  • No complete case/control contrast is available.
  • Critical dataset warnings must be resolved.

Next Steps

  • Resolve critical warnings before downstream analysis.

Analysis Preparation Checklist

4/6 ready

Group labels reviewed

Blocked

No complete case/control grouping exists yet.

Review the sample grouping table and assign both case and control groups.

Minimum sample count met

Blocked

At least one group has fewer than 2 samples.

Choose a larger dataset or merge only scientifically valid groups.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Analysis readiness has blockers that must be resolved before DE.

Analysis preparation checklist contains blocked items.

No complete case/control or treatment/control contrast is available.

At least one comparison group has fewer than two samples.

Critical dataset warnings are present.

Study design is model-system or unclear and should be reviewed before analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Disease context Inflammatory bowel disease Disease context came from Normalization rules.
  • Likely case group Inflammatory bowel disease 24 samples
  • Likely control group No control group detected 0 samples

Intent Interpretation

  • Downgrade or exclusion reason Comparison: Unclear study design. Specimen: Biofluid. Comparison suitability: 0%. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Interpreted disease metadata: Inflammatory bowel disease.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 1 publication; 1 DOI available: PMID 38401525.
  • Publication context: Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024. PMID 38401525. DOI 10.1016/j.biopha.2024.116299.

Cautions

  • Comparison: Unclear study design. Specimen: Biofluid. Comparison suitability: 0%.
  • Downgraded for tissue search because it is a biofluid cohort.
  • Downgraded for tissue search because study design or specimen source is unclear.
  • Blood, plasma, or serum cohort downgraded because this ranking targets tissue tumor-vs-normal comparisons.
  • Unclear study design downgraded for patient tissue tumor-vs-normal search intent.
  • Missing or unclear metadata. Unclear study design downgraded for patient tissue tumor-vs-normal search intent.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Missing or unclear metadata. Comparison - Unclear study design. Specimen - Biofluid. Comparison suitability: 0%.
  • Missing or unclear metadata. Downgraded for tissue search because study design or specimen source is unclear.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

76 fields

Sample Group Preview

24 rows shown
Show Hide
Study totals: Case 24 | Control 0 | Unassigned 0 | Excluded 0 | Ambiguous 0 24 rows shown
Group Role Accession Title Source / characteristics Reason
Inflammatory bowel disease Case GSM7884318 SAL008 Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884319 NJ035 Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Non-responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884320 JC022 Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884321 PT015 Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Non-responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884322 NJ029 Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884323 NJ037 Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Non-responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884324 IL008 Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884325 H12003 Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Non-responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884326 H12004 Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884327 VR019 Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Non-responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884328 PAZ021 Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Non-responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884329 SJ039 Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884330 VV0011 (re-analysis) Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884331 GM0031 (re-analysis) Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884332 JC0121 (re-analysis) Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884333 RM0171 (re-analysis) Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884334 RM0101 (re-analysis) Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884335 VR0161 (re-analysis) Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884336 PAZ0161 (re-analysis) Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Non-responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884337 PM005_1 (re-analysis) Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Non-responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884338 VR0131 (re-analysis) Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Non-responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884339 RM0161 (re-analysis) Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Non-responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884340 D0051 (re-analysis) Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Non-responder; Time: Before initiation of treatment Case marker detected.
Inflammatory bowel disease Case GSM7884341 RS0041 (re-analysis) Blood Tissue: Blood; Disease state: Pediatric inflammatory bowel disease; Treatment: Anti-TNF; Response: Non-responder; Time: Before initiation of treatment Case marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.